This section is dedicated to publishing articles, expert blogs, and educational materials focused on Spartina® and tirzepatide. Developed in collaboration with leading professors and specialists, the content provides healthcare professionals with continuously updated knowledge, clinical perspectives, and practical insights to support evidence-based practice.
Obesity, a chronic disease affecting millions worldwide, necessitates lifestyle modifications as the primary treatment approach. Incretin-mimetic drugs like GLP-1 agonists offer metabolic benefits beyond weight loss, improving liver health and
Polycystic ovary syndrome (PCOS) affects women of reproductive age and is often linked to obesity and insulin resistance. A study on tirzepatide in women with PCOS and obesity showed significant
Tirzepatide, a dual GLP-1 and GIP receptor agonist, shows superior efficacy in weight reduction and metabolic improvement. In a phase 1 trial, tirzepatide led to significant weight loss, reduced energy
Tirzepatide (Spartina®) is a potent pharmacological agent for weight loss, achieving reductions of 25-30% and significant glycemic benefits in patients with T2DM. It is FDA-approved for T2DM, weight management, and
This website contains scientific and medical information intended exclusively for healthcare professionals (HCPs). If you are not a healthcare professional, please exit this site and visit www.spartina.ir
این وبسایت حاوی اطلاعات علمی و پزشکی است که صرفاً برای استفاده پزشکان طراحی شده است. اگر شما از کادر درمان نیستید، لطفاً این وبسایت را ترک کرده و به www.spartina.ir مراجعه کنید
